192 related articles for article (PubMed ID: 22662203)
1. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.
Villar VH; Vögler O; Martínez-Serra J; Ramos R; Calabuig-Fariñas S; Gutiérrez A; Barceló F; Martín-Broto J; Alemany R
PLoS One; 2012; 7(5):e37735. PubMed ID: 22662203
[TBL] [Abstract][Full Text] [Related]
2. Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein.
Villar VH; Vögler O; Barceló F; Gómez-Florit M; Martínez-Serra J; Obrador-Hevia A; Martín-Broto J; Ruiz-Gutiérrez V; Alemany R
J Nutr Biochem; 2014 Apr; 25(4):429-38. PubMed ID: 24491315
[TBL] [Abstract][Full Text] [Related]
3. Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma.
Villar VH; Vögler O; Barceló F; Martín-Broto J; Martínez-Serra J; Ruiz-Gutiérrez V; Alemany R
PLoS One; 2016; 11(5):e0155946. PubMed ID: 27219337
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
[TBL] [Abstract][Full Text] [Related]
7. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
8. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
[TBL] [Abstract][Full Text] [Related]
9. Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting P-glycoprotein.
Sun Y; Liu W; Wang C; Meng Q; Liu Z; Huo X; Yang X; Sun P; Sun H; Ma X; Peng J; Liu K
J Cell Physiol; 2019 Apr; 234(4):3685-3696. PubMed ID: 30171603
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation.
Contreras O; Villarreal M; Brandan E
Skelet Muscle; 2018 Feb; 8(1):5. PubMed ID: 29463296
[TBL] [Abstract][Full Text] [Related]
12. Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.
Alemany R; Moura DS; Redondo A; Martinez-Trufero J; Calabuig S; Saus C; Obrador-Hevia A; Ramos R; Villar VH; Valverde C; Vaz MA; Medina J; Felipe-Abrio I; Hindi N; Taron M; Martin-Broto J
Clin Cancer Res; 2018 Nov; 24(21):5239-5249. PubMed ID: 30037815
[No Abstract] [Full Text] [Related]
13. Ailanthone reverses multidrug resistance by inhibiting the P-glycoprotein-mediated efflux in resistant K562/A02 cells.
Han F; Liu G; Sun C; Wei J
Cell Mol Biol (Noisy-le-grand); 2018 Dec; 64(15):55-61. PubMed ID: 30672437
[TBL] [Abstract][Full Text] [Related]
14. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
15. [Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors].
Shan XY; Chen BA; Xia GH; Xu WL; Ding JH; Gao C; Sun YY; Wang J; Cheng J; Zhao G; Bao W; Song HH; Gao F; Wang F; Wang XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):90-5. PubMed ID: 20137125
[TBL] [Abstract][Full Text] [Related]
16. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
17. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH
Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872
[TBL] [Abstract][Full Text] [Related]
18. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
19. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases.
Seo SB; Hur JG; Kim MJ; Lee JW; Kim HB; Bae JH; Kim DW; Kang CD; Kim SH
Mol Cancer; 2010 Jul; 9():199. PubMed ID: 20663232
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Ammoun S; Schmid MC; Triner J; Manley P; Hanemann CO
Neuro Oncol; 2011 Jul; 13(7):759-66. PubMed ID: 21727212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
